FDA Approves Pfizer’s Tukysa Maintenance Regimen

The US Food and Drug Administration has approved Pfizer’s Tukysa, also known as tucatinib, in combination with trastuzumab and pertuzumab for maintenance treatment, according to Thepharmaletter.

The approval covers adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive, or HER2-positive, breast cancer following induction treatment. Thepharmaletter reported that Pfizer disclosed the FDA decision.

Approved maintenance combination

According to Thepharmaletter, the approved regimen combines Tukysa with trastuzumab and pertuzumab. The FDA approval identifies the regimen for maintenance treatment after induction treatment in the specified adult breast cancer population.

The report identifies tucatinib as the generic name for Tukysa and describes its use alongside trastuzumab and pertuzumab. The approved population is adults with unresectable locally advanced or metastatic HER2-positive breast cancer.

Key details from the FDA decision

• Company: Pfizer
• Product: Tukysa, or tucatinib
• Combination: trastuzumab and pertuzumab
• Treatment setting: maintenance treatment following induction treatment
• Population: adults with unresectable locally advanced or metastatic HER2-positive breast cancer

The FDA action concerns the combination regimen rather than Tukysa alone. The treatment setting described by Thepharmaletter is maintenance treatment following induction treatment.

Update for oncology sales professionals

For medical sales professionals focused on oncology, the event provides a defined FDA-approved use for Pfizer’s Tukysa regimen. Communications about the update can remain centered on the reported combination, maintenance setting, and named patient population.

The distinction between induction treatment and maintenance treatment is part of the approval description reported by Thepharmaletter. The report also specifies that the indication applies to adults and to unresectable locally advanced or metastatic HER2-positive breast cancer.

Pfizer’s disclosure, as reported by Thepharmaletter, adds an FDA approval for Tukysa in combination with trastuzumab and pertuzumab for this maintenance-treatment use.